ESHRE PGD Consortiumdata collection XIV-XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013
ESHRE PGD Consortiumdata collection XIV-XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013
复制标题
DOI：
10.1093/humrep/dex265
复制
发表时间：
2017-10-01
影响因子：
6.1
通讯作者：
Moutou, C.
中科院分区：
文献类型：
--
作者：
De Rycke, M.;Goossens, V.;Moutou, C.
研究问题：欧洲人类生殖与胚胎学会（ESHRE） PGD联盟的数据收集XIV-XV与数据收集I-XIII的累积数据相比如何？回答：第14次和第15次回顾性收集代表了关于PGD/PGS周期、妊娠和儿童的有价值的数据：观察到的主要趋势是阵列技术在PGS周期和PGD周期中以FISH检测染色体异常为代价的应用增加。已知情况：自1999年以来，PGD联盟收集、分析并发表了13个以前的数据集，以及前10年数据收集的概述。研究设计、规模、持续时间：使用FileMaker Pro数据库（版本5-12）从每个参与中心收集数据。单独的预先设计的FileMaker Pro文件用于周期，怀孕和婴儿记录。该研究记录了2011年和2012年历年的月经周期，并对这些月经周期导致的怀孕和婴儿进行了随访（直到2013年10月）。参与者/材料、设置、方法：数据由71个中心（PGD联盟的正式成员）提交。数据不完整或不一致的记录被排除在计算之外。修正、计算和表格由专家共同撰写。主要结果和偶发因素的作用：对于数据收集十四至十五，71个中心报告了11637个周期的卵母细胞回收（OR）数据，以及对2147例妊娠和1755例出生婴儿的随访细节。染色体异常总共报告了1953个OR周期，x连锁疾病的性别鉴定144个周期，单基因疾病的OR周期3445个周期，PGS的OR周期6095个周期，社会性别鉴定的OR周期38个周期。从2010年到2012年，基因检测阵列在PGS中的使用从4%增加到20%，在PGD周期中用于染色体异常的使用从6%增加到13%；囊胚期活检的摄取（从< 1%到7%）仅在结构染色体异常的周期中观察到，同时应用阵列比较基因组杂交。局限性和谨慎的原因：研究结果适用于71个参与研究的中心，可能不代表PGD的全球趋势。研究结果的更广泛含义：年度数据收集为数据挖掘和PGD/PGS实践的趋势提供了重要的资源。研究经费/竞争利益：无。
STUDY QUESTION: How does the data collection XIV-XV of the European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium compare with the cumulative data for data collections I-XIII?SUMMARY ANSWER: The 14th and 15th retrospective collection represents valuable data on PGD/PGS cycles, pregnancies and children: the main trend observed is the increased application of array technology at the cost of FISH testing in PGS cycles and in PGD cycles for chromosomal abnormalities.WHAT IS KNOWN ALREADY: Since 1999, the PGD Consortium has collected, analysed and published 13 previous data sets and an overview of the first 10 years of data collections.STUDY DESIGN, SIZE, DURATION: Data were collected from each participating centre using a FileMaker Pro database (versions 5-12). Separate predesigned FileMaker Pro files were used for the cycles, pregnancies and baby records. The study documented cycles performed during the calendar years 2011 and 2012 and follow-up of the pregnancies and babies born which resulted from these cycles (until October 2013).PARTICIPANTS/MATERIALS, SETTINGS, METHOD: Data were submitted by 71 centres (full PGD Consortium members). Records with incomplete or inconsistent data were excluded from the calculations. Corrections, calculations and tables were made by expert co-authors.MAIN RESULTS AND THE ROLE OF CHANCE: For data collection XIV-XV, 71 centres reported data for 11 637 cycles with oocyte retrieval (OR), along with details of the follow-up on 2147 pregnancies and 1755 babies born. A total of 1953 cycles to OR were reported for chromosomal abnormalities, 144 cycles to OR for sexing for X-linked diseases, 3445 cycles to OR for monogenic diseases, 6095 cycles to OR for PGS and 38 cycles to OR for social sexing. From 2010 until 2012, the use of arrays for genetic testing increased from 4% to 20% in PGS and from 6% to 13% in PGD cycles for chromosomal abnormalities; the uptake of biopsy at the blastocyst stage (from < 1% up to 7%) was only observed in cycles for structural chromosomal abnormalities, alongside the application of array comparative genomic hybridization.LIMITATIONS, REASONS FOR CAUTION: The findings apply to the 71 participating centres and may not represent worldwide trends in PGD.WIDER IMPLICATIONS OF THE FINDINGS: The annual data collections provide an important resource for data mining and for following trends in PGD/PGS practice.STUDY FUNDING/COMPETING INTEREST(S): None.